| scholarly article | Q13442814 |
| P50 | author | Donal J Brennan | Q89761373 |
| Helena C Bartels | Q90600010 | ||
| P2093 | author name string | Paul Downey | |
| James D Postle | |||
| P2860 | cites work | Biological functions of hCG and hCG-related molecules | Q21245541 |
| The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A | Q22009032 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Early placental insulin-like protein (INSL4 or EPIL) in placental and fetal membrane growth | Q24541305 | ||
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| Assignment of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ hybridization to mitotic and meiotic chromosomes | Q28115988 | ||
| Evolutionary perspectives into placental biology and disease | Q28593517 | ||
| Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A | Q28616725 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Circulating cell-free fetal messenger RNA levels after fetoscopic interventions of complicated pregnancies. | Q33240483 | ||
| Obstetrical complications associated with abnormal maternal serum markers analytes | Q33387732 | ||
| Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants | Q33950055 | ||
| Structure and Function of Alpha-Fetoprotein | Q34269410 | ||
| mRNA of placental origin is readily detectable in maternal plasma. | Q34960254 | ||
| Morbidly adherent placenta treatments and outcomes | Q35142151 | ||
| Key questions and answers about pregnancy-associated plasma protein-A. | Q35947007 | ||
| Prenatal diagnosis: progress through plasma nucleic acids | Q36673937 | ||
| Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta | Q36696063 | ||
| Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress | Q36735536 | ||
| Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome | Q36919730 | ||
| Relaxin, its receptor (RXFP1), and insulin-like peptide 4 expression through gestation and in placenta accreta | Q37019967 | ||
| Placenta accreta: spectrum of US and MR imaging findings | Q37323079 | ||
| The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study | Q37532100 | ||
| Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section | Q38155308 | ||
| First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery | Q81575462 | ||
| Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta | Q82492801 | ||
| Regulation of trophoblast invasion: the role of matrix metalloproteinases | Q86361310 | ||
| The invasive phenotype of placenta accreta extravillous trophoblasts associates with loss of E-cadherin | Q87170304 | ||
| Placental Pathologic Associations With Morbidly Adherent Placenta: Potential Insights Into Pathogenesis | Q88784971 | ||
| MRI of Placenta Accreta, Placenta Increta, and Placenta Percreta: Pearls and Pitfalls. | Q50567546 | ||
| Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation. | Q52858621 | ||
| Characterization of four human pregnancy-associated plasma proteins. | Q53708836 | ||
| Histopathology of Placenta Creta: Chorionic Villi Intrusion into Myometrial Vascular Spaces and Extravillous Trophoblast Proliferation are Frequent and Specific Findings With Implications for Diagnosis and Pathogenesis. | Q53806599 | ||
| Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. | Q53873373 | ||
| Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. | Q54197341 | ||
| Increased cell-free fetal DNA in plasma of two women with invasive placenta. | Q54277406 | ||
| [Involvement of matrix metalloproteinase-2, -9, and tissue inhibitors of metalloproteinase-1, 2 in occurrence of the accrete placenta]. | Q54597811 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Placental apoptosis in normal human pregnancy | Q59367743 | ||
| Second-trimester maternal serum markers and placenta accreta | Q61859468 | ||
| Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein | Q67900177 | ||
| First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications | Q73070066 | ||
| Characterization of tubal and decidual leukocyte populations in ectopic pregnancy: evidence that endometrial granulated lymphocytes are absent from the tubal implantation site | Q74455981 | ||
| Risk factors for placenta accreta | Q77360650 | ||
| Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels | Q77941769 | ||
| Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes | Q80473246 | ||
| Expression of epidermal growth factor receptor and c-erbB-2 oncoprotein in trophoblast populations of placenta accreta | Q81126630 | ||
| Low maternal serum levels of pregnancy-associated plasma protein-A during the first trimester are associated with subsequent preterm delivery with preterm premature rupture of membranes | Q81502930 | ||
| The up side of decidual natural killer cells: new developments in immunology of pregnancy | Q38164418 | ||
| Physiological and pathological consequences of cellular senescence. | Q38235660 | ||
| Placenta accreta spectrum: accreta, increta, and percreta | Q38498819 | ||
| Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination | Q38693692 | ||
| The depletion of MARVELD1 leads to murine placenta accreta via integrin β4-dependent trophoblast cell invasion | Q38697333 | ||
| Downregulation of miR-29a/b/c in placenta accreta inhibits apoptosis of implantation site intermediate trophoblast cells by targeting MCL1. | Q38729792 | ||
| Does the presence of placental basal plate myometrial fibres increase the risk of subsequent morbidly adherent placenta: a case-control study | Q38975037 | ||
| Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy | Q39009519 | ||
| Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. | Q39362975 | ||
| First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes | Q39880571 | ||
| Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and -5. | Q40168727 | ||
| Alpha-fetoprotein: a biomarker for pregnancy outcome | Q40490386 | ||
| Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media | Q40960014 | ||
| Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. | Q40994470 | ||
| What is the role of matrix metalloproteinase-2 in placenta percreta? | Q41471516 | ||
| First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation | Q41499364 | ||
| Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women | Q41648760 | ||
| Placenta accreta is associated with elevated maternal serum alpha-fetoprotein | Q42066685 | ||
| Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblasts | Q42482873 | ||
| Placental Pathologic Associations with Morbidly Adherent Placenta: Potential insights into Pathogenesis | Q42496622 | ||
| Matrix metalloproteinases-2, -3 and -9 in human term placenta | Q42513878 | ||
| Occult placenta accreta: the missing link in the diagnosis of abnormal placentation | Q42516039 | ||
| Placental basal plate formation is associated with fibrin deposition in decidual veins at sites of trophoblast cell invasion | Q42517701 | ||
| Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study | Q43688745 | ||
| Elevated first trimester PAPP--a is associated with increased risk of placenta accreta | Q43738398 | ||
| The management of placenta percreta: conservative and operative strategies | Q44001120 | ||
| Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia | Q44121356 | ||
| Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta | Q44200909 | ||
| Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane. | Q44204070 | ||
| Temporal and Spatial Expression of Integrins and Their Extracellular Matrix Ligands at the Maternal-Fetal Interface in the Rhesus Monkey During Pregnancy1 | Q44406719 | ||
| Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes | Q44885652 | ||
| Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. | Q45295203 | ||
| Placenta accreta is associated with decreased decidual natural killer (dNK) cells population: a comparative pilot study | Q46850378 | ||
| First-trimester combined screening for Down syndrome: prediction of low birth weight, small for gestational age and pre-term delivery in a cohort of non-selected women | Q47245087 | ||
| Implantation site intermediate trophoblasts in placenta cretas. | Q47322787 | ||
| Senescence and Telomere Homeostasis Might Be Involved in Placenta Percreta-Preliminary Investigation | Q47435120 | ||
| Screening for placental insufficiency in high-risk pregnancies: is earlier better? | Q47849025 | ||
| First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). | Q47860634 | ||
| Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth | Q47864591 | ||
| Identification and characterization of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation. | Q48012992 | ||
| Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta | Q48114217 | ||
| Can venous ProBNP levels predict placenta accreta? | Q48916335 | ||
| Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast | Q50128917 | ||
| FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology | Q50190712 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | molecular biology | Q7202 |
| placenta accreta | Q517856 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 1507674 | |
| P577 | publication date | 2018-07-03 | |
| P1433 | published in | Disease Markers | Q15756044 |
| P1476 | title | Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers | |
| P478 | volume | 2018 |
| Q99583663 | Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis |
| Q61836670 | Ultrasound screening at 11-14 weeks of pregnancy for diagnosis of placenta accreta in mothers with a history of cesarean section |
Search more.